ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0912

Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis

Kristin Wipfler1, Joanna Zeiger2, Teresa Simon3, Stuart Kassan4 and Kaleb Michaud5, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Canna Research Foundation, Boulder, CO, 3Physicians Research Center Consultant to ForWard, Toms River, NJ, 4Colorado Arthritis Associates, Lakewood, CO, 5University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: genetics, pain, Patient reported outcomes, rheumatoid arthritis, Therapy, complementary

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Fatty acid amide hydrolase (FAAH) is a serine hydrolase that breaks down the endocannabinoid/cannabinoid receptor agonist anandamide. Variants in the FAAH gene have been associated with pain susceptibility as well as with cannabis use. In addition, FAAH inhibition has been shown to have anti-arthritic and pain reduction effects in collagen-induced arthritis mouse models. The objective of this study was to examine relationships between FAAH variants and cannabis use as well as real-world effectiveness in pain management for individuals with rheumatoid arthritis (RA).

Methods: Data were provided by adults with RA participating in FORWARD, The National Databank for Rheumatic Diseases, who provided blood samples and answered questions about cannabis use (defined as use of products containing THC and/or CBD). Genotyping was performed with the Illumina Infinium Global Screening Array platform, and non-silent common FAAH variants (minor allele frequency >0.5; SNPs rs324419 and rs324420) were included in this analysis. Logistic regression models for cannabis use vs nonuse and for self-reported effectiveness in pain management (helpful vs not helpful) were generated for each variant by presence or absence of the minor allele. Models were adjusted for age, sex, white race, cigarette smoking history, calendar year, RA duration, BMI, glucocorticoid use, NSAID use, opioid use, and Rheumatic Disease Comorbidity Index (RDCI).

Results: A total of 365 participants met inclusion criteria, 129 (35.3%) of whom reported cannabis use as a treatment for arthritic pain. Among users, 52% reported that cannabis was helpful in reducing their pain, 30% reported that it was not helpful, and 18% reported that they were not sure (Table 1). Genotype distributions of both variants are presented in Table 2. In multivariable models for each of the two variants that met inclusion criteria (Figure 1), one (rs324419 C >T) was associated with cannabis use (OR [95% CI] 1.9 [1.1, 3.3]; p=0.03) and the other (rs324420 C >A) was associated with self-reported effectiveness (5.2 [1.6, 16.7]; p< 0.01).

Conclusion: Our results indicate that individuals with RA and the genotype CT or TT at rs324419 are twice as likely to use cannabis for arthritis pain management, and cannabis users with RA and the genotype CA or AA at rs324420 have five times greater odds of finding cannabis effective in reducing their pain. FAAH has previously been implicated separately in pain perception, in cannabis use, and in reduction of arthritis severity in mouse models, but this is the first study linking FAAH with cannabis use and real-world pain management in rheumatoid arthritis.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Wipfler, None; J. Zeiger, None; T. Simon, Janssen, Bristol-Myers Squibb(BMS); S. Kassan, None; K. Michaud, None.

To cite this abstract in AMA style:

Wipfler K, Zeiger J, Simon T, Kassan S, Michaud K. Associations Between Fatty Acid Amide Hydrolase Variants and Response to Cannabis Use for Pain Management in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/associations-between-fatty-acid-amide-hydrolase-variants-and-response-to-cannabis-use-for-pain-management-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-fatty-acid-amide-hydrolase-variants-and-response-to-cannabis-use-for-pain-management-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology